Company / R&D Expense
Outlook Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$41.8M
FY2025
5-year range
$18.5M / $41.8M
FY2021-FY2025
Trend
+75.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $19M to $42M over the past 6 years.
Based on SEC 10-K filings.
$42M in FY2025 with a 5-year CAGR of +11.9%.
Improved from $19M to $42M over the past 6 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +11.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +11.9%, indicating consistent growth.
- In FY2025, r&d expense increased 75.4% year-over-year.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.8M | +75.4% |
| FY2020 | $23.8M | +28.6% |
| FY2019 | $18.5M | -22.3% |
| FY2018 | $23.8M | -27.3% |
| FY2017 | $32.8M | -15.7% |
| FY2016 | $38.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026